Zhitong HK Stock Market Early Briefing | 107 New Drugs Added to the 2026 National Essential Medical Insurance Drug List; Federal Reserve Officials Turn Hawkish Again

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- China released the 2026 edition of the National Basic Medical Insurance Drug Catalog, adding 107 new drugs including CAR-T therapies to improve patient accessibility.
- Wall Street equities experienced mixed performance as the S&P 500 fell 0.4% and Nvidia suffered its largest weekly drop since April 2025.…
Disclaimer

[Top Headlines]

2026 Edition of National Essential Medical Insurance Drug List Released, Adding 107 New Drugs

The 2026 edition of the National Medical Insurance Drug List was released on November 14, 2026, adding 107 new drugs, including 51 Class 1 innovative drugs, setting a new historical high.

The new list will officially take effect on January 1, 2027. Highlights include:

  1. CAR-T included in basic medical insurance for the first time: JW Therapeutics' Relma-cel injection has become the first CAR-T product to enter the National Medical Insurance Directory. With the original price exceeding one million yuan, patients' out-of-pocket expenses are expected to drop to within 100,000 yuan after reimbursement.

  2. Non-factor drugs for hemophilia included: Fentolane sodium and Emicizumab fill gaps in the directory.

  3. Outstanding performance of domestic innovative drugs: Products from Innovent Biologics' Mazdutide (the first domestically developed dual-target weight loss and glucose-lowering original drug), Baili Tianheng's Yizekang (included in the first year of listing), and Henlius' Hansizhuang were all included.

  4. Increased payment cap for ophthalmic drugs: The medical insurance payment limit for two anti-VEGF ophthalmic drugs has been adjusted from "a maximum cumulative total of 9 doses per eye" to "14 doses," marking the first increase in nine years.

  5. Assisted reproductive drugs included for the first time: Recombinant Human Follicle Stimulating Hormone Alpha and Luteinizing Hormone Alpha for Injection have entered the directory.

This year, the commercial health insurance innovative drug directory continues to be adjusted synchronously, adding 12 new drugs (including the world's first solid tumor CAR-T and China's first gene therapy drug for hemophilia), bringing the total to 28 types. Meanwhile, a linkage mechanism between the commercial insurance directory and the basic medical insurance directory has been established, with two varieties from the 2025 commercial insurance directory transferred to basic medical insurance this year.

[Market Outlook]

Nasdaq Rose 2.27% Last Week; NVIDIA Fell 13%, Marking Largest Weekly Drop Since April 2025

Overnight, US stocks closed mixed. The Dow Jones Industrial Average rose by 50.46 points from the previous trading day to close at 52,347.55, a gain of 0.1%; the S&P 500 Index fell by 30.73 points to close at 7,561.67, a decline of 0.4%; the Nasdaq Composite Index fell by 229.82 points to close at 25,136.27, a decline of 0.91%. Last week, the Dow rose 2.07%, the Nasdaq rose 2.27%, and the S&P 500 rose 2.51%.

The "Magnificent Seven" tech giants in US stocks showed mixed performance. Meta Platforms rose 2.90%, and Apple rose 0.39%, hitting a new all-time closing high. NVIDIA fell more than 2%, with its stock price dropping 13% cumulatively last week, marking the largest weekly decline since April 2025. It also marked the sixth consecutive week of declines, setting the longest streak of consecutive drops since 2012, with over $573 billion wiped off its market capitalization last week. Chip stocks declined, with the Philadelphia Semiconductor Index closing down 3.43%. AMD fell more than 8%, SanDisk fell more than 5%, Western Digital fell 5%, Broadcom and ARM fell more than 4%, and Lam Research and Seagate Technology fell more than 3%.

The Nasdaq Golden Dragon China Index closed up 0.84%, with popular Chinese concept stocks showing mixed performance. Hang Seng Index ADRs rose, closing at 23,729.90 points on a pro-rata basis, up 92.30 points or 0.39% compared to the Hong Kong closing.

WTI crude oil futures for the nearest continuous contract at the New York Mercantile Exchange rose by $0.37 to $89.11 per barrel, a gain of 0.42%. COMEX gold futures for the nearest continuous contract fell by $5.30, a decline of 0.14%, to $3,880.0 per ounce.

[Hot Topics Preview]

After Inflation Exceeded Expectations, Federal Reserve Official Collins Stated: Further Rate Hikes Needed Soon

Boston Fed President Susan Collins stated that as inflationary pressures spread to more areas, it would be necessary for the Federal Reserve to raise interest rates further "soon." However, she did not clarify the magnitude and pace of rate hikes, nor did she directly respond to whether she supported a 50 basis point hike in December.

Chicago Fed President Goolsbee stated on Friday that the latest inflation data was concerning, and the Federal Reserve might still need to take further action to curb rising prices and rebuild market confidence in the central bank's ability to control inflation. In an interview that day, Goolsbee said, "I think the Federal Reserve clearly has a lot of work to do to continue rebuilding its credibility."

Foreign Exchange Deposit Reserve Ratio for Financial Institutions Raised to 6%

On November 15, the People's Bank of China's adjustment to the foreign exchange deposit reserve ratio for financial institutions officially took effect, raising the ratio from the current 4% to 6%. This increase helps promote balance between supply and demand in the foreign exchange market and breaks the self-fulfilling expectation of RMB appreciation.

Guotai Haitong Asset Management Clarifies Online Rumors: Never Conducted Transactions with Private Equity Funds as Counterparties

Recently, rumors circulated online regarding "an institution entrusting funds to a company's investment advisor for management, conducting agreed repurchases with private equity funds, and experiencing repurchase defaults." In response, Guotai Haitong Asset Management issued a clarification announcement on November 14, stating that the online content was unrelated to Shanghai Guotai Haitong Securities Asset Management Co., Ltd., and the rumored business was not conducted by Guotai Haitong Asset Management. Guotai Haitong Asset Management has long prohibited any form of cash bond or repurchase business with private equity funds and has never conducted transactions with private equity funds as counterparties. Guotai Haitong Asset Management adheres to independent investment decision-making and execution, establishing strict access, approval, and risk control mechanisms, and there are no circumstances related to the aforementioned rumored business.

WuXi JiNu-B (02126) Plans to Issue Approximately 61.1855 Million Subscription Shares at a Discount of About 2.97%, Raising HK$160 Million

WuXi JiNu-B (02126) announced that on November 15, 2026, the company entered into subscription agreements with China Hongqiao Holdings Limited or its designated entities and Novo Vista Limited Partnership, proposing to issue a total of approximately 61.1855 million subscription shares to them. The subscription price per share is HK$2.615, representing a discount of approximately 2.97% to the closing price per share of HK$2.695 reported on the Stock Exchange on the last trading day. The total subscription amount is HK$160 million.

CDB Leasing (01606) Plans to Purchase IT Computer Equipment for RMB 981 Million

CDB Leasing (01606) issued an announcement stating that the company, as the buyer, entered into this product procurement agreement with the seller (Guangdong Shuhuan Zhilian Technology Co., Ltd.) on November 13, 2026. Accordingly, the seller agreed to sell and the buyer agreed to purchase the procurement targets, with a total consideration of approximately RMB 981 million. The procurement targets are information technology computer equipment.

China Boton Group (03318) Subsidiary Injects RMB 160 Million into Shandong Ganghong Biotechnology to Acquire 49% Equity Stake

Upon completion, Shenzhen Boton will hold 49% of the target company's expanded registered capital. Therefore, the target company will be accounted for as an associate of the company, and its financial results will not be consolidated into the group's consolidated financial statements.

Xinhua Winshare (00811) Acquires 100% Equity Interest in Sichuan Ethnic Publishing House Co., Ltd.

The company received notification from Sichuan Xinhua Publishing and Distribution Group that this transaction has been approved by the superior state-owned assets supervision and administration department.

China Education Group Holding (00839) Estimates Annual Net Profit Attributable to Shareholders to be Approximately RMB 630 Million to RMB 770 Million

The above expected performance takes into account expected non-cash impairment losses (net of deferred tax) of approximately RMB 1.06 billion to RMB 1.14 billion, involving certain non-current assets of two cash-generating units located in Henan Province and Sichuan Province, China. This mainly reflects a downward revision in estimated future cash flows due to changes in the market environment and operational planning.

Liqiang Eye Care-B (06622): Self-Developed Innovative Drug Jingyouling® (Cyclosporine Ophthalmic Gel) Receives Marketing Approval from the National Medical Products Administration

The indication is to promote tear secretion in patients with dry eye disease, applicable to patients with reduced tear production caused by dry eye, to improve their ocular signs.

Hansoh Pharmaceutical (03692): Aumolertinib Marketing Authorization Receives Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use

Hansoh Pharmaceutical (03692) announced that on November 12, 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorization for Aumolertinib for the treatment of non-small cell lung cancer.

TCL Electronics (01070) Shows Strong Growth in First Three Quarters; Adjusted Net Profit Attributable to Parent Company Reaches HK$2.243 Billion, Up 54.5% Year-on-Year

In the first three quarters of 2026, the group's internet business revenue increased by 28.2% year-on-year to HK$2.695 billion. Among these, the expansion of higher-margin international internet business continued to accelerate, with its share of internet business revenue increasing by 17.0 percentage points year-on-year, driving the overall gross margin of the internet business up by 4.6 percentage points year-on-year to 60.9%, continuing to contribute high-quality profits.

[Stock Spotlight]

InnoCare Pharma-B (07630): EU Marketing Application for Senaparib Expected to be Approved This Month

InnoCare Pharma announced that the board of directors decided to use no more than HK$100 million to repurchase H-shares in the open market, with all required funds coming from the company's own resources. In addition, the company may further repurchase H-shares within the repurchase mandate granted by the shareholders' meeting, depending on market conditions.

Notably, Senaparib already received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in September. Goldman Sachs stated that InnoCare Pharma's management indicated at the GS Asia Healthcare Corporate Day that the EU marketing application for Senaparib is expected to be approved this month, based on the positive opinion received from CHMP in September.

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.